Literature DB >> 24807718

Recombinant covalently closed circular hepatitis B virus DNA induces prolonged viral persistence in immunocompetent mice.

Zhihua Qi1, Gaiyun Li1, Hao Hu1, Chunhui Yang1, Xiaoming Zhang1, Qibin Leng1, Youhua Xie2, Demin Yu3, Xinxin Zhang3, Yueqiu Gao4, Ke Lan5, Qiang Deng5.   

Abstract

It remains crucial to develop a laboratory model for studying hepatitis B virus (HBV) chronic infection. We hereby produced a recombinant covalently closed circular DNA (rcccDNA) in view of the key role of cccDNA in HBV persistence. A loxP-chimeric intron was engineered into a monomeric HBV genome in a precursor plasmid (prcccDNA), which was excised using Cre/loxP-mediated DNA recombination into a 3.3-kb rcccDNA in the nuclei of hepatocytes. The chimeric intron was spliced from RNA transcripts without interrupting the HBV life cycle. In cultured hepatoma cells, cotransfection of prcccDNA and pCMV-Cre (encoding Cre recombinase) resulted in accumulation of nuclear rcccDNA that was heat stable and epigenetically organized as a minichromosome. A mouse model of HBV infection was developed by hydrodynamic injection of prcccDNA. In the presence of Cre recombinase, rcccDNA was induced in the mouse liver with effective viral replication and expression, triggering a compromised T-cell response against HBV. Significant T-cell hyporesponsiveness occurred in mice receiving 4 μg prcccDNA, resulting in prolonged HBV antigenemia for up to 9 weeks. Persistent liver injury was observed as elevated alanine transaminase activity in serum and sustained inflammatory infiltration in the liver. Although a T-cell dysfunction was induced similarly, mice injected with a plasmid containing a linear HBV replicon showed rapid viral clearance within 2 weeks. Collectively, our study provides an innovative approach for producing a cccDNA surrogate that established HBV persistence in immunocompetent mice. It also represents a useful model system in vitro and in vivo for evaluating antiviral treatments against HBV cccDNA. Importance: (i) Unlike plasmids that contain a linear HBV replicon, rcccDNA established HBV persistence with sustained liver injury in immunocompetent mice. This method could be a prototype for developing a mouse model of chronic HBV infection. (ii) An exogenous intron was engineered into the HBV genome for functionally seamless DNA recombination. This original approach could be also extended to other viral studies. (iii) rcccDNA was substantially induced in the nuclei of hepatocytes and could be easily distinguished by its exogenous intron using PCR. This convenient model system affords the opportunity to test antivirals directly targeting HBV cccDNA.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24807718      PMCID: PMC4097776          DOI: 10.1128/JVI.01024-14

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

1.  Viral clearance without destruction of infected cells during acute HBV infection.

Authors:  L G Guidotti; R Rochford; J Chung; M Shapiro; R Purcell; F V Chisari
Journal:  Science       Date:  1999-04-30       Impact factor: 47.728

Review 2.  Memory CD8 T-cell differentiation during viral infection.

Authors:  E John Wherry; Rafi Ahmed
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

Review 3.  Stealth and cunning: hepatitis B and hepatitis C viruses.

Authors:  Stefan F Wieland; Francis V Chisari
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

4.  Contribution of CpG motifs to the immunogenicity of DNA vaccines.

Authors:  D M Klinman; G Yamshchikov; Y Ishigatsubo
Journal:  J Immunol       Date:  1997-04-15       Impact factor: 5.422

5.  Heterogeneity and common features of defective hepatitis B virus genomes derived from spliced pregenomic RNA.

Authors:  S Günther; G Sommer; A Iwanska; H Will
Journal:  Virology       Date:  1997-11-24       Impact factor: 3.616

6.  Quantitation of covalently closed circular hepatitis B virus DNA in chronic hepatitis B patients.

Authors:  Danny Ka-Ho Wong; Man-Fung Yuen; HeJun Yuan; Simon Siu-Man Sum; Chee-Kin Hui; Jeff Hall; Ching-Lung Lai
Journal:  Hepatology       Date:  2004-09       Impact factor: 17.425

7.  In vivo and in vitro expression of defective hepatitis B virus particles generated by spliced hepatitis B virus RNA.

Authors:  O Rosmorduc; M A Petit; S Pol; F Capel; F Bortolotti; P Berthelot; C Brechot; D Kremsdorf
Journal:  Hepatology       Date:  1995-07       Impact factor: 17.425

8.  High-level hepatitis B virus replication in transgenic mice.

Authors:  L G Guidotti; B Matzke; H Schaller; F V Chisari
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

9.  DNA-mediated immunization to the hepatitis B surface antigen in mice: aspects of the humoral response mimic hepatitis B viral infection in humans.

Authors:  M L Michel; H L Davis; M Schleef; M Mancini; P Tiollais; R G Whalen
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-06       Impact factor: 11.205

10.  A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients.

Authors:  S Günther; B C Li; S Miska; D H Krüger; H Meisel; H Will
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

View more
  30 in total

Review 1.  Progress With Developing Use of Gene Editing To Cure Chronic Infection With Hepatitis B Virus.

Authors:  Abdullah Ely; Buhle Moyo; Patrick Arbuthnot
Journal:  Mol Ther       Date:  2016-02-26       Impact factor: 11.454

Review 2.  Genome editing and the next generation of antiviral therapy.

Authors:  Daniel Stone; Nixon Niyonzima; Keith R Jerome
Journal:  Hum Genet       Date:  2016-06-08       Impact factor: 4.132

3.  A non-viral CRISPR/Cas9 delivery system for therapeutically targeting HBV DNA and pcsk9 in vivo.

Authors:  Chao Jiang; Miao Mei; Bin Li; Xiurui Zhu; Wenhong Zu; Yujie Tian; Qiannan Wang; Yong Guo; Yizhou Dong; Xu Tan
Journal:  Cell Res       Date:  2017-01-24       Impact factor: 25.617

Review 4.  CRISPR/Cas9: at the cutting edge of hepatology.

Authors:  Francis P Pankowicz; Kelsey E Jarrett; William R Lagor; Karl-Dimiter Bissig
Journal:  Gut       Date:  2017-05-09       Impact factor: 23.059

5.  HDM2 Promotes NEDDylation of Hepatitis B Virus HBx To Enhance Its Stability and Function.

Authors:  Ningning Liu; Jinfang Zhang; Xiaohai Yang; Tong Jiao; Xin Zhao; Wenxia Li; Jianhua Zhu; Pu Yang; Jianping Jin; Jirun Peng; Zhiwei Li; Xin Ye
Journal:  J Virol       Date:  2017-07-27       Impact factor: 5.103

Review 6.  Recent advances in the study of hepatitis B virus covalently closed circular DNA.

Authors:  Mengying Ji; Kanghong Hu
Journal:  Virol Sin       Date:  2017-12-21       Impact factor: 4.327

7.  STING signaling activation inhibits HBV replication and attenuates the severity of liver injury and HBV-induced fibrosis.

Authors:  Yuqi Li; Minjing He; Ziyu Wang; Zhiyun Duan; Zhiwei Guo; Ziteng Wang; Ruijie Gong; Tianhao Chu; Jiabin Cai; Bo Gao
Journal:  Cell Mol Immunol       Date:  2021-11-22       Impact factor: 11.530

Review 8.  Beyond Metabolism: Role of the Immune System in Hepatic Toxicity.

Authors:  Kenneth L Hastings; Martin D Green; Bin Gao; Patricia E Ganey; Robert A Roth; Gary R Burleson
Journal:  Int J Toxicol       Date:  2020 Mar/Apr       Impact factor: 2.032

9.  Two-way molecular ligation for efficient conversion of monomeric hepatitis B virus DNA constructs into tandem dimers.

Authors:  Li Zong; Yanli Qin; Haodi Jia; Huailiang Zhou; Chaoyang Chen; Ke Qiao; Jiming Zhang; Yongxiang Wang; Jisu Li; Shuping Tong
Journal:  J Virol Methods       Date:  2016-03-26       Impact factor: 2.014

10.  Cre/LoxP-HBV plasmids generating recombinant covalently closed circular DNA genome upon transfection.

Authors:  Robert L Kruse; Xavier Legras; Mercedes Barzi
Journal:  Virus Res       Date:  2020-11-06       Impact factor: 3.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.